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Abstract: To develop a nomogram predicting probability of axillary
pathologic complete response (pCR) in patients with cytologically
proven axillary node-positive breast cancer who received neoadjuvant
chemotherapy (NAC).
The current management of axillary intervention in node-positive
breast cancer patients who received NAC is axillary lymph node
dissection (ALND) regardless of axillary pCR.
We reviewed the records of 415 patients with cytologically proven
node-positive breast cancer that were treated with NAC followed by
surgery between 2008 and 2012 at Severance Hospital, Yonsei Uni-
versity Health System. Baseline patient and tumor characteristics,
chemotherapy regimen, and tumor and nodal responses were analyzed.
A nomogram was developed using a binary logistic regression model
with a training cohort and validated in an independent cohort of 110
patients.
Axillary pCR was achieved in 38.8% of the patients who underwent
ALND after NAC. Axillary pCR was associated with initial clinical
nodal status, negative estrogen receptor status, positive human epider-
mal growth factor receptor 2 (HER2) status with trastuzumab, and
clinical nodal and tumor responses. A nomogram was developed based
on the clinical and statistically significant predictors. It had good
discrimination performance (AUC 0.82, 95% CI, 0.78–0.86) and
calibration fit. The nomogram was independently validated, indicating
the good predictive power of the model (AUC 0.80, 95% CI,
0.72–0.88).
Our nomogram might help predict axillary pCR after NAC in
patients with initially node-positive breast cancer. Patients with a high
probability of achieving axillary pCR could be spared ALND, avoiding
postoperative morbidity.
(Medicine 94(43):e1720)a Kim, MD, Jegyu o Park, MD,
m, MD, PhD
pathologic complete response, PR = progesterone receptor,
ROC = receiver-operating characteristics, SLNB = sentinel lymph
node biopsy, SUV = standardized uptake value.
INTRODUCTION
N eoadjuvant chemotherapy (NAC) has become a wide-spread treatment modality in locally advanced breast
cancer.1,2 It can safely downstage operable breast tumors so
that conservation surgery can be used as an alternative to
mastectomy.3 Furthermore, the neoadjuvant setting offers the
opportunity to assess the response to NAC by an in vivo
chemosensitivity test.
NAC results in the negative conversion of a metastatic
axillary lymph node in 22% to 41%4–8 of patients with cyto-
logically confirmed node-positive breast cancer. An axillary
pathologic complete response (pCR) is associated with excel-
lent prognosis,4,8 and patients who achieve axillary pCR can be
spared axillary lymph node dissection (ALND), avoiding post-
operative morbidities such as lymphedema, arm pain, and
reduced arm movement.9,10 Until now, axillary pCR has could
only be determined by performing ALND.
The current standard for axillary staging in clinically node-
negative patients is sentinel lymph node biopsy (SLNB).11
ALND is recommended for axillary intervention in patients
with clinically node-positive breast cancer who received
NAC,11 because the feasibility of SLNB is uncertain in those
patients.6,7 Recent prospective multicenter trials found that
SLNB following NAC had a low detection rate (80.1–
92.7%) and a relatively high false-negative rate (12.6–
14.2%).5,12 SLNB could be available, however, with more or
less a 90% detection rate and a 10% false-negative rate under
certain conditions, including the detection of 2 or more SLNs
and the use of dual mapping. Those findings suggest that along
with SLNB, additional tools might be helpful to evaluate the
axillary lymph node response to NAC in patients with cytolo-
gically proven node-positive breast cancer and to identify
patients in whom ALND could be omitted.
A nomogram in a clinical setting is considered a compre-
hensive predictive tool that can estimate the probabilities or
risks or clinical outcomes. In previous studies, nomograms
provided detailed probabilities or risks of clinical outcomes
for clinicians and patients making decisions in the management
of breast cancer.13,14 There are few well-designed nomograms
predicting the probability of axillary pCR in the literature, and
the implications of providing a detailed probability of axillary
pCR in patients who receive NAC are well not established.
For those reasons, we investigated the factors that pre-
established a nomogram calculating the
CR in patients with cytologically proven
breast cancer who received NAC.
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PATIENTS AND METHODS
Study Population
Patients with clinical T1–T4, N1–N3, and M0 primary
invasive breast cancer who received NAC followed by curative
surgery between January 2008 and July 2014 at Severance
Hospital (Seoul, South Korea) were retrospectively reviewed.
Among 662 patients, 2 male patients, 120 patients without
cytologically proven axillary lymph node metastasis, and 8
patients who underwent ALND only were excluded. All the
525 patients had node-positive disease confirmed by fine-needle
aspiration biopsy at presentation and underwent radical oper-
ation of the primary tumor with concurrent ALND.
Among 525 patients, 415 patients treated between January
2008 and December 2012 were evaluated and used as a training
set to develop a nomogram. The nomogram was validated
independently using a set of 110 patients. All the patients in
the validation set also had cytologically confirmed node-
positive disease and received NAC followed by curative surgery
between January 2013 and July 2014 in the same institution
(Fig. 1). This study was reviewed and approved by the Institu-
tional Review Board of Severance Hospital, Yonsei University
Health System (2014-2789-001).
Clinicopathological Characteristics and
Evaluation of Responses to NAC
Patients were divided into 2 categories of age 35 and
below, versus above age 35.15,16 The body mass index (BMI)
was calculated on the date of the first course of NAC. BMI
25 kg/m2 was classified to obesity according to Asia-Pacific
Region Criteria of WHO classification.17
Before NAC, estrogen receptor (ER), progesterone receptor
(PR), human epidermal growth factor receptor 2 (HER2), Ki67
expression, and histologic grade of the diagnostic core biopsy
Kim et alsample were evaluated. Tumors with10% nuclear-stained cells
were considered positive for ER and PR. Tumors with HER2 3þ
overexpression determined by immunohistochemistry or HER2
FIGURE 1. Flowchart of patient selection. NAB ¼ needle aspiration b
2 | www.md-journal.comamplification determined by in situ fluorescencewere considered
to overexpress HER2.18 Ki67 expression 14% was considered
high.19 Histologic grade was assessed using the modified
Bloom–Richardson classification.20 The clinical and pathologic
stage was assessed according to the 7th edition of the AJCC
cancer staging system.21 Clinical N3 was defined by physical
examination, cytological confirmation, and imaging including
MRI and PET-CT.
The biologic subtypes were categorized into 4 subgroups
according to ER, PR, and HER2 status as follows: luminal A,
ER positive and/or PR positive, and HER2 negative; luminal B,
ER positive and/or PR positive, and HER2 positive; HER2-
enriched, ER negative and PR negative and HER2 positive;
triple-negative breast cancer, ER negative and PR negative and
HER2 negative.
Chemotherapy regimens were classified as anthracycline
and taxane, anthracycline and no taxane, or no anthracycline
and no taxane.
The clinical tumor size was measured as the largest single
tumor diameter on ultrasound before and after the completion of
NAC. Malignant microcalcification was determined by the
presence of intratumoral microcalcification on ultrasound. Mul-
tifocality/multicentricity was defined by the presence of biopsy-
proven multifocal and/or multicentric tumors in the
ipsilateral breast.
The clinical tumor response rate to the NACwas calculated
by the rate of tumor size reduction, comparing the largest single
tumor diameter on the ultrasound image at baseline to the
largest single tumor diameter on the ultrasound image after
NAC ([icT-ycT]/icT). Classification according to the Response
Evaluation Criteria in Solid Tumors ver. 1.122 was also utilized.
A complete response was defined as the complete or near-
complete resolution of the lesion. A partial response was
defined as a 30% or greater decrease in the size of the lesion.
Medicine  Volume 94, Number 43, October 2015Disease progression was defined as a 20% or greater increase in
the size of the lesion. All other responses were defined as stable
disease. The clinical nodal response was determined by
iopsy, ALND ¼ axillary lymph node dissection.
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ultrasound description of the presence or absence of suspicious
and malignant-appearing lymph nodes after the completion
of NAC.
All the patients underwent breast and axillary surgery
within 6 weeks of completing NAC. The type of breast surgery
was selected according to the preferences of the surgeon and the
patient. ALND was performed for axillary nodal metastasis
regardless of accompanying SLNB. Patients with cytologically
proven supraclavicular and/or infraclavicular lymph nodes were
treated with concurrent neck node dissection. The pathologic
response was evaluated using the largest single diameter of the
invasive tumor in the surgical specimen. Axillary pCR was
defined as the absence of macrometastasis and micrometastasis.
Model Construction and Performance Evaluation
We built a nomogram based on a binary logistic regression
model with the significant and predefined predictors in the
training cohort. The model was then used to predict the prob-
abilities of individual patients achieving axillary pCR to NAC.
The performance of the model was quantified with respect
to discrimination and calibration. Discrimination is the predic-
tor’s ability to separate patients with different responses or
events. The discriminatory abilities of the model were assessed
by measuring the area under the receiver-operating character-
istics (ROC) curve. Calibration is the agreement between the
frequencies of observed outcomes and the probabilities pre-
dicted by the model. The calibration plot was evaluated using
the Hosmer–Lemeshow goodness-of-fit test and visualized
by plots.
Statistical Analysis
Relationships between variables were studied using stan-
dard tests. Continuous variables were compared using 2-sample
t tests, and categorical variables were compared between and
among groups using a Chi-square test or a Fisher exact test.
Univariate and multivariate binary logistic regression analyses
were used to identify factors associated with axillary pCR after
NAC. Odds ratios and 95% confidence intervals were calcu-
lated. All statistical tests were 2-sided, and P-values less than
0.05 were considered statistically significant.
Analyses were performed using Statistical Program for
Medicine  Volume 94, Number 43, October 2015Social Science (SPS) version 20.0 (IBM, Inc., Chicago, IL) and
R Statistical Package (Institute for Statistics and Mathematics,
Vienna, Austria, Ver. 2.9.2 and Ver. 3.1.1, www.R-project.org).
RESULTS
Patient Characteristics
The baseline patient and tumor characteristics for the 415
patients in the training set are shown in Table 1. Axillary pCR
was achieved in the 38.3% of the patients. Patients with axillary
pCR tended to be younger (35 years), and were more likely to
have tumors with early clinical and nodal stage compared with
patients with axillary non-pCR. Tumors with high histologic
grade, negative ER and PR status, positive HER2 status with
trastuzumab, and high Ki67 expression were significantly more
common in patients with axillary pCR. BMI, histologic type,
and malignant microcalcification were not significantly differ-
ent between the patients with and without axillary pCR, respect-
ively. There was a trend for a higher percentage of triple-
negative (31.4%) and HER2-enriched breast cancers (23.9%)
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.among the patients with axillary pCR compared with those with
axillary non-pCR (16.8% and 15.2%, respectively; P< 0.001).
The baseline patient and tumor characteristics for 110
patients in the validation set are shown in Supplemental Table 1.
Clinicopathologic Response to Neoadjuvant
Chemotherapy
The median clinical tumor diameters before and after NAC
were 3.2 cm (range, 0.2–10.0 cm) and 1.6 cm (range, 0–
10.0 cm), respectively (Table 2). The clinical tumor size
throughout the treatment was significantly smaller in the
patients with axillary pCR. The clinical response rate of the
breast tumor was 51% overall and was significantly higher in
the patients with axillary pCR compared with that in the patients
with axillary non-pCR (67% and 42%, respectively; P< 0.001).
The rate of clinical complete response of the breast tumor was
significantly higher in the patients with axillary pCR compared
with that in the patients with axillary non-pCR (24.5% and
8.2%, respectively; P< 0.001).
The rate of tumor pCR (ypT0/Tis) was significantly higher
in the patients with axillary pCR compared with that in the
patients with axillary non-pCR (43.4% and 10.2%, respectively;
P< 0.001). Among the patients who did not achieve axillary
pCR, 68.8% had ypN1 disease, 22.7% had ypN2 disease, and
8.6% had ypT3 disease. The overall rate of pCR in both the
breast and the axilla (ypT0/Tis, ypN0) was 16.6%.
Clinicopathologic response to NAC of the patients in the
validation set is shown in Supplemental Table 2.
Significant Predictors of Axillary pCR
The univariate logistic regression analysis of the 415
patients in the training set who underwent ALND after NAC
showed that the proportion of patients with axillary pCR
increased with high histologic grade, young age, early clinical
tumor stage, and nodal stage. Breast conserving surgery, taxane-
based chemotherapy, negative ER status, negative PR status,
positive HER2 status (especially with trastuzumab treatment),
high Ki67 expression, and absence of multifocality/multicen-
tricity were associated with axillary pCR as the clinical tumor or
clinical nodal response.
The multivariate logistic regression analysis showed that
early clinical nodal stage, negative ER status, positive HER2
status with trastuzumab treatment, and clinical tumor and nodal
response were significantly correlated with an increased prob-
ability of achieving axillary pCR (Table 3).
Development and Validation of the Nomogram
We constructed a nomogram based on the clinically and
statistically significant variables. The significant variables that
can be assessed in preoperative evaluations in the univariate
analysis were years of age (35 vs. >35), clinical tumor stage
(cT1, cT2, cT3, or cT4), histologic grade (well, moderate, or
poor), Ki67 (low vs. high expression), and regimen of NAC
(anthracycline and taxane, anthracycline and no taxane, or
taxane and no anthracycline).
Figure 2 illustrates the nomogram to calculate the prob-
ability of achieving axillary pCR. The total nomogram score is
calculated by summing up the scores for each of the variables.
Nomogram for Prediction of Axillary PCRThe total score can then be used to assign a probability of
achieving axillary pCR to individual patients using the scale at
the bottom of the figure.
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TABLE 1. Baseline Patient and Tumor Characteristics of 415 Patients Treated With Neoadjuvant Chemotherapy
Variables
All Patients,
N¼ 415
Axillary pCR (%),
N¼ 159 (38.3)
Axillary Non-pCR (%),
N¼ 256 (61.7) P-Value
Age (years)
Median (range) 50 (26–76)
35 31 (7.5) 18 (11.3) 13 (5.1) 0.019
>35 384 (92.5) 141 (88.7) 243 (94.9)
BMI
BMI<25 kg/m2 288 (69.4) 111 (69.8) 177 (69.1) 0.86
25 kg/m2 127 (30.6) 48 (30.2) 79 (30.9)
Clinical tumor stage
cT1 117 (28.2) 51 (32.1) 66 (25.8) 0.005
cT2 241 (58.1) 97 (61.0) 144 (56.3)
cT3 38 (9.2) 10 (6.3) 28 (10.9)
cT4 19 (4.6) 1 (0.6) 18 (7.0)
Clinical nodal stage
cN1–N2 349 (84.1) 147 (92.5) 202 (78.9) <0.001
cN3 66 (15.9) 12 (7.5) 54 (21.1)
Chemotherapy received
Anthracycline and taxane 355 (85.6) 131 (82.4) 224 (87.5) 0.008
Anthracycline, no taxane 26 (6.3) 7 (4.4) 19 (7.4)
Taxane, no anthracycline 34 (8.2) 21 (13.2) 13 (5.1)
Type of surgery
Mastectomy 252 (60.7) 79 (49.7) 173 (67.6) <0.001
BCS 163 (39.3) 80 (50.3) 83 (32.4)
Histologic type
IDC 402 (96.9) 158 (99.4) 244 (95.3) 0.063
ILC 5 (1.2) 0 (0) 5 (2.0)
Other 8 (1.9) 1 (0.6) 7 (2.7)
Histologic grade
Well differentiated 60 (14.5) 14 (8.8) 46 (18.0) <0.001
Moderately differentiated 226 (54.5) 79 (49.7) 147 (57.4)
Poorly differentiated 129 (31.1) 66 (41.5) 63 (24.6)
Estrogen receptor
Positive 237 (57.1) 68 (42.8) 169 (66.0) <0.001
Negative 178 (42.9) 91 (57.2) 87 (34.0)
Progesterone receptor
Positive 149 (35.9) 42 (26.4) 107 (41.8) 0.001
Negative 266 (64.1) 117 (73.6) 149 (58.2)
HER2
Negative 280 (67.5) 97 (61.0) 183 (71.5) <0.001
Positive with trastuzumab 13 (3.1) 12 (7.5) 1 (0.4)
Positive without trastuzumab 122 (29.4) 50 (31.4) 72 (28.1)
Ki67
Low 141 (34.0) 38 (23.9) 103 (40.2) 0.003
High 197 (47.5) 88 (55.3) 109 (42.6)
Unknown 77 (18.6) 33 (20.8) 44 (17.2)
Malignant microcalcification
Yes 135 (32.5) 48 (30.2) 87 (34.0) 0.42
No 280 (67.5) 111 (69.8) 169 (66.0)
Multifocality/multicentricity
Yes 59 (14.2) 15 (9.4) 44 (17.2) 0.028
No 356 (85.8) 144 (90.6) 212 (82.8)
Biologic subtype
Luminal A 187 (45.1) 47 (29.6) 140 (54.7) <0.001
Luminal B 58 (14.0) 24 (15.1) 34 (13.3)
HER2 enriched 77 (18.6) 38 (23.9) 39 (15.2)
TNBC 93 (22.4) 50 (31.4) 43 (16.8)
BCS¼ breast conserving surgery, BMI¼ body mass index, HER2¼ human epidermal growth factor receptor 2, IDC¼ invasive ductal carcinoma,
ILC¼ invasive lobular carcinoma, pCR¼ pathologic complete response, TNBC¼ triple negative breast cancer.
Kim et al Medicine  Volume 94, Number 43, October 2015
4 | www.md-journal.com Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
TABLE 2. Clinical and Pathologic Response to Neoadjuvant Chemotherapy
Variables
All Patients,
N¼ 415
Axillary pCR (%),
N¼ 159 (38.3)
Axillary Non-pCR (%),
N¼ 256 (61.7) P-Value
Clinical tumor size before chemotherapy,
median (range), cm
3.2 (0.2–10.0) 2.8 (0.5–7.4) 3.4 (0.2–10.0) 0.002
Clinical tumor size after chemotherapy,
median (range), cm
1.6 (0–10.0) 1.0 (0–6.8) 2.0 (0–10.0) <0.001
Clinical response of breast tumor
Complete response 60 (14.5) 39 (24.5) 21 (8.2) <0.001
Partial response 235 (56.6) 96 (60.4) 139 (54.3)
Stable disease 113 (27.2) 23 (14.5) 90 (35.2)
Disease progression 7 (1.7) 1 (0.6) 6 (2.3)
Clinical tumor response rate, median (range), % 51 (67 to 100) 67 (20 to 100) 42 (67 to 100) <0.001
Clinical nodal response
Yes 169 (40.7) 92 (57.9) 77 (30.1) <0.001
No 246 (59.3) 67 (42.1) 179 (69.9)
Pathologic T classification
ypT0 95 (22.9) 69 (43.4) 26 (10.2) <0.001
ypT1 236 (56.9) 82 (51.6) 154 (60.2)
ypT2 67 (16.1) 7 (4.4) 60 (23.4)
ypT3 9 (2.2) 1 (0.6) 8 (3.1)
ypT4 8 (1.9) 0 (0) 8 (3.1)
Pathologic N classification
ypN0 159 (38.3) 159 (100) —
ypN1 176 (42.4) — 176 (68.7)
ypN2 58 (14.0) — 58 (22.7)
ypN3 22 (5.3) — 22 (8.6)
Combination of tumor and nodal response
ypT0/Tis, ypN0 69 (16.6)
ypTþ, ypN0 90 (21.7)
ypT0/Tis, ypNþ 26 (6.3)
ypTþ, ypNþ 230 (55.4)
Medicine  Volume 94, Number 43, October 2015 Nomogram for Prediction of Axillary PCRThe ROC curve of the nomogram is shown in Figure 3A.
The area under the ROC curve was 0.82 (95% CI, 0.78–0.86),
indicating the good predictive power of the model. The cali-
bration plot (Fig. 3B) showed good agreement between the
predicted and observed probabilities according to a Hosmer–
Lemeshow test (P-value¼ 0.94).
The model was applied to an independent cohort of 110
patients who met the eligibility criteria for validation.
Figure 4A shows the ROC curve for the validation set. The
area under the ROC curve was 0.80 (95% CI, 0.72–0.88),
indicating the substantial predictive power of the model in the
validation set. The calibration plot (Fig. 4B) yielded good
agreement between the expected and actual events in the
pCR¼ pathologic complete response.validation set. Hosmer–Lemeshow test of goodness-of-fit
was not significant (P-value¼ 0.19), indicating the good fit
of the model.
DISCUSSION
Predicting pCR of the axillary lymph node after NAC in
patients with breast cancer and cytologically confirmed nodal
metastasis is important for understanding patient outcomes
as well as for identifying patients in whom ALND might
be omitted. We performed a retrospective review of patient
data and developed a prediction model based on the
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.clinicopathologic characteristics of the primary tumor to esti-
mate the probability of achieving axillary pCR. We then
validated the model in an independent cohort of patients.
In this study, axillary pCR was achieved in 38.3% (159 of
415) of the patients, which is similar to the rates seen in previous
studies.4–7 It has been shown that tumors that are ER-nega-
tive,23,24 HER2-positive with trastuzumab treatment,25,26 have a
high histologic grade,27 or have high levels of Ki67 expression28
are more likely to achieve pCR. As anticipated, patients achiev-
ing axillary pCR not only had lower disease burden of the
primary tumor and the lymph node but also had a higher
percentage of tumors that achieved pCR. The clinical tumor
response rate and the nodal response to NAC were also highly
associated with axillary pCR.
Our nomogram is in line with previous studies predict-
ing axillary pCR after NAC in patients with cytologically
proven nodal metastasis,4,29 but it has several advantages
compared with previous models. Although the previous
models had acceptable performance with standard vari-
ables, they lacked proliferation scores and did not consider
tumor and nodal responses to the NAC. In addition, they
were not validated in a separate sample but internally
validated by bootstrapping.
We developed a nomogramwith improved performance by
adding proliferation markers such as histologic grade and Ki67
www.md-journal.com | 5
TABLE 3. Univariate and Multivariate Analysis for Axillary Pathologic Complete Response (n¼415)
Univariate Multivariate
Variable OR 95% CI P-Value OR 95% CI P-Value
Age (years) 0.022 0.20
35 — — — —
>35 0.42 0.20–0.88 0.55 0.22–1.40
Clinical tumor stage 0.025 0.19
cT1 — — — —
cT2 0.87 0.56–1.36 0.75 0.44–1.30
cT3 0.46 0.21–1.04 0.38 0.14–1.06
cT4 0.07 0.01–0.56 0.22 0.26–1.93
Clinical nodal stage <0.001 <0.001
cN1–N2 — — — —
cN3 0.31 0.16–0.59 0.19 0.08–0.47
Histologic grade <0.001 0.11
Well differentiated — — — —
Moderately differentiated 1.77 0.92–3.41 1.79 0.82–3.94
Poorly differentiated 3.44 1.73–6.87 2.66 1.06–6.70
Type of surgery <0.001 0.24
Mastectomy — — — —
BCS 2.11 1.41–3.17 1.37 0.82–2.28
Chemotherapy received 0.011 0.62
Anthracycline and taxane — — — —
Anthracycline, no taxane 0.63 0.26–1.54 0.59 0.21–1.72
Taxane, no anthracycline 2.76 1.34–5.70 1.09 0.39–3.07
Estrogen receptor <0.001 0.032
Positive — — — —
Negative 2.60 1.73–3.91 2.08 1.07–4.04
Progesterone receptor 0.002 0.39
Positive — — — —
Negative 2.00 1.30–3.08 1.33 0.70–2.52
HER2 0.007 0.036
Negative — — — —
Positive without trastuzumab 1.31 0.85–2.03 1.11 0.64–1.90
Positive with trastuzumab 22.64 2.90–176.70 21.49 2.06–224.06
Ki67 0.003 0.31
Low — — — —
High 2.19 1.37–3.49 1.60 0.88–2.93
Unknown 2.03 1.13–3.65 1.45 0.71–2.96
Multifocality/multicentricity 0.030 0.10
Yes — — — —
No 1.99 1.07–3.72 1.88 0.88–4.02
Clinical tumor response 8.51 4.28–16.92 <0.001 5.51 2.44–12.43 <0.001
Clinical nodal response <0.001 <0.001
No — — — —
Yes 3.19 2.11–4.82 2.78 1.65–4.66
BCS¼ breast conserving surgery, CI¼ confidence interval, HER2¼ human epidermal growth factor receptor 2, OR¼ odds ratio.
FIGURE 2. Nomogram for prediction of the probability of axillary pathologic complete response. NAC ¼ neoadjuvant chemotherapy,
A ¼ anthracycline, T ¼ taxane, pCR ¼ pathologic complete response.
Kim et al Medicine  Volume 94, Number 43, October 2015
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FIGURE 3. The receiver-operating characteristics (ROC) curve and
FIGURE 4. The receiver-operating characteristics (ROC) curve and
the calibration plot of the nomogram in the validation set. (A) ROC
Medicine  Volume 94, Number 43, October 2015 Nomogram for Prediction of Axillary PCRexpression. Histologic grade and Ki67 expression level have
been investigated previously as predictive markers for
responses to NAC,28,30 so we incorporated them into the
nomogram after finding that they were associated with axil-
lary pCR in our univariate analysis. Another advantage of the
nomogram is that the clinical responses of the primary tumor
and the axillary lymph node to NAC were considered import-
ant factors for the prediction of axillary pCR. Ultrasound is
included in the standard workup procedures around the NAC
in our institution, because the primary tumor response can be
easily obtained by measuring the tumor diameter by ultra-
sound before and after NAC. The lymph node response can
the calibration plot of the nomogram in the training set. (A) ROC
curve with AUC¼0.82 (95% CI, 0.78–0.86). (B) Calibration plot
of the nomogram (Hosmer–Lemeshow test: P-value¼0.94).also be reflected by the presence or absence of pathologic
lymph node after NAC. A recently published study demon-
strated the potential utility of axillary ultrasound after NAC
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.and before surgery to evaluate residual nodal disease in
women presenting with node-positive breast cancer, showing
that axillary ultrasound reduced the false-negative rate of
SLNB from 12.6% to 9.8%.31 In addition, an independent
cohort was included to validate our nomogram, and the
independent validation indicated the good predictive power
of the model.
During the study period, trastuzumab was not added to
the NAC as a standard treatment in patients with HER2-
positive tumors because it was not covered at the time by the
national health insurance in Korea. Neoadjuvant trastuzumab
therapy was approved in late 2013. Therefore, only 9.6% of
curve with AUC¼0.80 (95% CI, 0.72–0.88). (B) Calibration plot
of the nomogram (Hosmer–Lemeshow test: P-value¼0.19).the patients in our study received trastuzumab with their
NAC, because they were participants in clinical trials (ie,
NeoALTTO). As the number of patients receiving
www.md-journal.com | 7
neoadjuvant trastuzumab has increased in recent years, the
model construction might be modified to reflect the current
use of neoadjuvant trastuzumab and the corresponding
increased axillary pCR rate. Previous trials reported good
response rates with taxane-containing regimens,32 and a
taxane and no-anthracycline regimen was associated with a
higher rate of axillary pCR in our study. Of 34 patients with a
regimen based on taxane only, 13 patients were treated with
concurrent trastuzumab, and 12 of those patients achieved
axillary pCR. That result might be explained by the trastu-
zumab treatment in combination with taxane in HER2-
positive tumors and not by the taxane-only regimen itself.
The biologic tumor subtype was associated with axillary
pCR in this study, and HER2-enriched and triple-negative
breast cancers were especially likely to achieve axillary pCR
compared with luminal breast cancer. The rate of axillary pCR
was 49.4% (38 of 77 patients) in the HER2-enriched tumors and
53.8% (50 of 93 patients) in the triple-negative tumors in our
study. Our results are somewhat discordant with those of a
previous study33 based on ACOSOG Z1071, which showed
64.7% and 49.4% rates of axillary pCR in HER2-enriched and
triple-negative tumors, respectively. The markedly lower rate of
axillary pCR in HER2-enriched tumors in our study might be
related to the apparently lower rate of neoadjuvant trastuzumab
treatment (9.6%) compared with that in the study based on
ACOSOGZ1071 (88.9%). Although the biologic tumor subtype
was associated with axillary pCR, we did not incorporate the
biologic tumor subtype into the nomogram. Because the defi-
nition of biologic subtype varies somewhat among studies34 and
the factors that determine the biologic subtype (ER, PR, and
HER2 status) were incorporated in our nomogram separately,
we chose to exclude the biologic subtype from the nomogram
for simplicity.
The nomogram uses easily assessable clinicopathologic
variables, allowing simple and rapid calculation of the prob-
ability of achieving axillary pCR. It can be used to help
surgeons and patients making treatment decision and can
also be utilized in clinical trials. The nomogram should be
considered an ancillary tool, however, that provides measur-
able information but does not provide an actual clinical
recommendation.
There are several limitations to our study. First, our
nomogram was not validated in an external cohort. Although
we validated it with an independent dataset, the validation data
were extracted from the same institution that produced the
training set. Second, as with any retrospective study, there is
the issue of selection bias. Because the study included only
patients who had cytologically confirmed nodal metastasis,
patients who had false-negative fine-needle aspiration biopsy
but received NAC were not included. Finally, the assessment of
the clinical tumor and nodal responses to NAC using ultrasound
alone might be somewhat subjective.35,36 Moreover, anatomical
measurement alone might be insufficient to detect the tumor and
nodal responses without considering functional and metabolic
changes. Future efforts are needed to include more objective
imaging tools like MRI37 and to reflect functional responses
through changes in the maximum standardized uptake value
(SUVmax) on PET-CT.
38,39
CONCLUSION
Our study demonstrates a nomogram for calculating the
Kim et alprobability of achieving axillary pCR in patients with cytolo-
gically proven node-positive breast cancer based on the known
clinicopathologic features before and after NAC. The
8 | www.md-journal.comnomogram can help identify patients with a high probability
of achieving axillary pCRwho could be spared ALND, avoiding
postoperative morbidity. To select such patients in actual
clinical practice, further research on the accurate detection of
residual tumor in the axilla must be explored in depth.
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